dilmapimod (SB-681323) / GSK - LARVOL DELTA

Bioinformatic approach for repurposing immunomodulatory drugs for lepromatous leprosy. (PubMed, Int J Mycobacteriol) - "Consistently, glucosamine, binimetinib, talmapimod, dilmapimod, andrographolide, and VX-702 might have a possible beneficial effect coupled with LL treatment. Based on our drug repurposing analysis, immunomodulatory drugs might have a promising potential to be explored further as therapeutic options or to alleviate symptoms in LL patients."

Immunomodulating • Journal • Oncology • IFNG • IL1B

SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS (clinicaltrials.gov) - P2; N=90; Completed; Sponsor: GlaxoSmithKline; Recruiting ➔ Completed

Clinical • Trial completion